Krystal Biotech (KRYS) Operating Expenses (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Operating Expenses data on file, last reported at $62.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 20.68% year-over-year to $62.7 million; the trailing twelve-month figure through Mar 2026 stood at $238.7 million (up 6.18% YoY), and the FY2025 full-year result was $227.8 million, up 1.36% from the prior year.
• Operating Expenses held at $62.7 million in Q1 2026, from $62.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $62.8 million in Q4 2025 to a low of $28.8 million in Q2 2022.
• A 5-year average of $48.3 million and a median of $50.2 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 249.91% in 2022 and dropped 8.07% in 2025, its largest moves.
• Tracing KRYS's Operating Expenses over 5 years: stood at $34.8 million in 2022, then climbed by 11.86% to $38.9 million in 2023, then climbed by 27.94% to $49.8 million in 2024, then rose by 26.27% to $62.8 million in 2025, then retreated by 0.27% to $62.7 million in 2026.
• Business Quant data shows KRYS's Operating Expenses at $62.7 million in Q1 2026, $62.8 million in Q4 2025, and $56.4 million in Q3 2025.